Literature DB >> 28196759

Follow-up MR imaging of PI-RADS 3 and PI-RADS 4 prostate lesions.

Elke Hauth1, Horst Jaeger2, Horst Hohmuth3, Meinrad Beer4.   

Abstract

OBJECTIVE: To determine the rate of malignancy after follow-up MR imaging of the prostate in PI-RADS 3 lesions without core biopsy and PI-RADS 4 lesions after negative initial core biopsy.
MATERIALS AND METHODS: We performed follow-up MRI in 46/72 (64%) patients with PI-RADS 3 lesions and 26/72 (36%) patients with PI-RADS 4 lesions in baseline MRI.
RESULTS: The rate of malignancy in PI-RADS 3 lesions was 4% (2/46) and in PI-RADS 4 lesions 69% (18/26).
CONCLUSIONS: Follow-up MRI for PI-RADS 3 lesions should be performed. For PI-RADS 4 lesions with initial negative biopsy we recommend an instant repeat core biopsy.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biopsy; Diagnosis; Follow-up; MR imaging; Prostate cancer

Mesh:

Year:  2017        PMID: 28196759     DOI: 10.1016/j.clinimag.2017.01.016

Source DB:  PubMed          Journal:  Clin Imaging        ISSN: 0899-7071            Impact factor:   1.605


  3 in total

1.  Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate.

Authors:  M Boschheidgen; L Schimmöller; S Doerfler; R Al-Monajjed; J Morawitz; F Ziayee; D Mally; M Quentin; C Arsov; P Albers; G Antoch; T Ullrich
Journal:  Sci Rep       Date:  2022-04-25       Impact factor: 4.996

2.  Axumin (18F-Fluciclovine) PET imaging in men exhibiting no clinically significant cancer on initial negative biopsy of PI-RADS 4 and 5 regions of interest.

Authors:  Ezequiel Becher; Shawn Karls; Angela Tong; James S Wysock; Samir S Taneja; William C Huang; Herbert Lepor
Journal:  World J Urol       Date:  2022-10-05       Impact factor: 3.661

3.  Multiparametric magnetic resonance imaging ultrasound-guided fusion biopsy during active surveillance: A single-centre study.

Authors:  Kilian Röthlin; Stefania Zamboni; Marco Moschini; Patrick Stucki; Luca Afferi; Philipp Baumeister; Agostino Mattei
Journal:  Arab J Urol       Date:  2020-04-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.